Monitoring Visit Trip Reports: How to Write Them

A monitoring visit trip report (also called a monitoring visit report, or MVR) is the formal written record a Clinical Research Associate (CRA) or site monitor produces after every site visit conducted during a clinical trial. It documents what was reviewed, what was found, and what needs to happen next — and under ICH E6(R2) it is not an optional courtesy to the sponsor but a required element of the trial’s quality management system and audit trail.

This guide covers the report’s regulatory basis, its standard structure, how to write findings that actually drive corrective action, and the mistakes that make trip reports weak evidence during a sponsor audit or regulatory inspection.

Why the Trip Report Is a Regulatory Document, Not Just Internal Paperwork

ICH E6(R2) Section 5.18.6 requires that monitoring reports — both on-site and centralized — be submitted to the sponsor, including appropriate sponsor management and CRO staff, in a timely manner, with sufficient detail to allow verification of compliance with the monitoring plan and to support follow-up on any issues identified. The report is the documented evidence that monitoring actually happened, that it covered what the monitoring plan said it would cover, and that anything wrong was flagged and tracked to resolution.

That evidentiary role is what separates a good trip report from a merely adequate one. Under Section 5.18.3, monitoring exists to protect subject rights and well-being, confirm that reported data are accurate, complete, and verifiable against source, and confirm the trial is being conducted in compliance with the approved protocol, Good Clinical Practice, and applicable regulatory requirements. Section 5.18.4 lists the recurring activities a monitor performs to check those three things — informed consent verification, source data verification (SDV), investigational product accountability, and review of essential/regulatory document currency, among others. The trip report is where the outcome of each of those checks gets written down in a form a sponsor, auditor, or inspector can later reconstruct and rely on. A report that only says a visit “went well” gives none of that; a report that names the specific document reviewed, the specific discrepancy found, and the specific corrective action assigned is what the audit trail actually requires.

Standard Structure of a Monitoring Visit Trip Report

Formats vary by sponsor and CTMS/eTMF platform, but a compliant trip report consistently contains the same functional sections.

1. Visit Metadata

Visit type — Site Initiation Visit (SIV), Interim Monitoring Visit (IMV), or Close-Out Visit (COV) — since each carries a different scope and checklist.
Protocol number, site number, and investigator name.
Date of visit and date of report.
Monitor name and, where a co-monitor or the CRO’s clinical team lead attended, their name too.
Persons met at the site (PI, sub-investigator, coordinator, pharmacy staff, as applicable).
Enrollment status at the time of the visit (subjects screened, enrolled, ongoing, completed, withdrawn).

2. Findings by Category

This is the core of the report. Findings are conventionally grouped by the same functional areas the monitoring plan itself is organized around, so a reviewer can quickly see which parts of Section 5.18.4’s checklist were covered and what was found in each:

Regulatory documents — currency of the regulatory/essential document file (IRB/IEC approvals, current protocol and amendments, insurance, CVs and licenses), consistent with the essential-documents framework in ICH E6(R2) Section 8.
Informed consent — correct version in use, proper execution (dates, signatures, re-consent for amendments), and storage of the signed form.
Source data verification (SDV) — results of comparing case report form entries against source documents for the subjects reviewed, including any discrepancies and their disposition.
Investigational product (IP) accountability — dispensing/return/destruction records, storage conditions and temperature logs, and reconciliation against the accountability log.
Other protocol-specific items as applicable — adverse event/serious adverse event reporting timelines, protocol deviations identified since the last visit, and delegation-of-authority log currency.

Each finding should be written as a discrete, specific statement — what was reviewed, what was observed, and whether it conforms to the protocol/GCP requirement — rather than a general impression. “SDV performed for subjects 003 and 007; one AE onset date discrepancy identified between source and CRF for subject 003, query issued” is auditable. “SDV mostly fine, minor issues noted” is not.

3. Action Items

Every finding that requires a follow-up gets logged as a discrete action item with three fields, at minimum:

The specific action required (e.g., “resolve EDC query for subject 003 AE onset date”).
Due date for resolution.
Responsible party — named by role or individual (site coordinator, PI, sponsor CRA), not left implicit.

Carrying open action items forward from the previous report, with their status updated (open, closed, overdue), is what turns a series of trip reports into a working corrective-action log rather than a set of disconnected snapshots — and it is exactly the kind of trend an auditor or inspector will look for when assessing whether a site’s issues are actually being resolved.

4. Overall Assessment and Next Visit

A brief overall risk/compliance assessment of the site (e.g., site performing to protocol, site requires increased oversight) and the planned interval or date for the next visit, consistent with the trial’s monitoring plan.

How Report Content Differs by Visit Type

The trip report format stays constant, but the weight given to each section shifts with the visit type:

A Site Initiation Visit report is weighted toward confirming regulatory-document completeness, staff training, and IP/pharmacy readiness before enrollment opens — there is no SDV to perform yet, since no subjects have been enrolled.
An Interim Monitoring Visit report is where the bulk of recurring SDV, consent-execution, and IP-accountability findings accumulate over the course of the trial.
A Close-Out Visit report shifts to final reconciliation — confirming all queries are resolved, IP is fully accounted for and disposed of or returned, and the site’s essential document file is complete for archival.

Writing Practices That Hold Up Under Audit

Be specific and factual. Name the subject ID, document, date, or value involved in a finding rather than describing it in general terms. Vague findings cannot be independently verified later, which defeats the purpose of the record.
Separate observation from conclusion. Record what was seen, then state what it means for compliance, rather than blending the two into an unsupported summary judgment.
Submit promptly. ICH E6(R2) 5.18.6’s “timely manner” standard exists so that issues get escalated and corrected while they are still easy to fix — a report filed weeks after the visit undermines the sponsor’s ability to act on it and looks poor during an inspection.
Close the loop on prior action items before adding new ones. A reviewer reading a site’s report history should be able to see each issue from open to resolved.
Avoid the passive, no-fault construction. “Discrepancies were noted” without naming what, where, and by whom it will be resolved provides no basis for follow-up.
Route escalations correctly. Findings that indicate a potential protocol deviation, participant-safety issue, or GCP noncompliance should be escalated through the sponsor’s standard escalation path immediately, not held for inclusion in the next scheduled trip report.

Frequently Asked Questions

What’s the difference between a “monitoring visit report” and a “trip report”?

In practice the terms are used interchangeably in the industry for the same document — the report a monitor files after a site visit. Some organizations use “monitoring report” more broadly to include reports from remote or centralized monitoring activities that don’t involve physical travel to a site, reserving “trip report” specifically for on-site visits.

Who is responsible for writing the trip report?

The CRA or monitor who conducted the visit. Where a co-monitor or clinical team lead also attended, sponsor SOPs typically specify who has primary authorship, though both may be named as attendees.

How soon after a visit should the trip report be submitted?

ICH E6(R2) 5.18.6 requires submission “in a timely manner” without prescribing a fixed number of days; the specific turnaround requirement (commonly a matter of days, not weeks) is set by the sponsor’s monitoring plan or SOPs and should be treated as a compliance deadline, not a suggestion.

Does the trip report need to be signed?

Sponsor SOPs and the trial’s monitoring plan govern the exact sign-off requirements; because the report is part of the trial’s essential documentation and audit trail, it is standard practice for it to be reviewed and, in many systems, formally approved (with an audit-trail-visible sign-off) before it is finalized in the eTMF.

Where does the trip report live once it’s finalized?

As part of the trial’s essential/regulatory documentation, the finalized report is filed in the Trial Master File (or site-level Investigator Site File) system, where it remains available for sponsor QA review and regulatory inspection.